PainChek® enters home care market through pain management collaboration with MPS Connect – 22 December 2021 

Clarification to Appendix 4C – 3 December 2021

Results of AGM – 30 November 2021

Response to ASX Price and Volume Query – 30 November 2021

AGM Investor Update – 30 November 2021

PainChek to present at NWR Virtual Healthcare Day – 22 November 2021

Notice of Annual General Meeting / Proxy Form – 27 October 2021

September Quarterly Update – 22 October 2021

Appendix 4C- Quarterly cash flow report entities subject to Listing Rule 4.7B – 22 October 2021

Appendix 3Y – Change of Director’s Interest Notice – 16 September 2021

PainChek Infant study published in Lancet Digital Health – 2 September 2021

Financial Report for the year ended 30 June 2021 – 31 August 2021

Appendix 4E Preliminary Final Report – 31 August 2021

PainChek NSW OSR Taxation Assessment – 27 August 2021

Cleansing Statement – 20 August 2021

Application for quotation of securities – 20 August 2021

PainChek Adult App achieves 60% share of Australian Residential Aged Care market, new Infant App receives regulatory clearance for commercialisation in multiple markets – 29 July 2021

June 2021 Quarterly Update – 29 July2021

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B – 30 June 2021

PainChek to present at NWR Virtual Investor conference – 29 July 2021

PainChek to receive $1.25M milestone payment from Department of Health- 28 June 2021

PainChek achieves 127,000 licensed Residential Aged Care beds in Australia, marking 60% local market penetration – 3 June 2021

Change of Company Secretary – 2nd June 2021

PainChek Infant achieves regulatory clearance in multiple International markets – 20 May 2021

Appendix 3G Notification of issue, conversion or payment up of equity & securities – 18 May 2021

PainChek delivers 4th consecutive quarter of double digit RAC bed growth and UK sales and market activity increases – 29 April 2021

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B – 29 April 2021

PainChek receives CE Mark and TGA clearance for Universal app – 17 March 2021

PainChek to present at NWR Communications Virtual Investor Conference – 16 March 2021

Appendix 3G Notification of issue, conversion or payment up of equity & securities – 16 March 2021

Appendix 4D- Half Year Report to the Australian Securities Exchange – 25 February 2021

December 2020 Quarterly Update – 22 January 2021

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B – 22 January 2021

Successful completion of PainChek® Infant Face-Only clinical study for regulatory clearance filings – 22 January 2021

PainChek receives regulatory clearance from Health Canada – 19 November 2020

PainChek® expands presence in New Zealand through partnership with Medi-map Medication Management – 2 November 2020

PainChek® to enter Canadian homecare market in partnership with AlayaCare – 28 October 2020

PainChek® partners with Nulsen Group to improve pain detection in people with complex disabilities – 23 October 2020

PainChek partners with Ramsay Hospital Research Foundation & Edith Cowan University to improve pain management in frail patients – 2 October 2020

Confirmation of Release – PCK – PCK Expands Integration Partnerships with CMS Providers – 17 August 2020

Confirmation of Release – PCK – Amended Release – Acceptance of Patent Application in China – 14 August 2020

Confirmation of Release – PCK – PainChek Granted Patent in China – 14 August 2020

PainChek completes $10 million Placement  – 11 August 2020

June 2020 Quarterly Update – 28 July 2020

Appendix 4E Preliminary Final Report to the Australian Securities Exchange – 30 June 2020

PainChek® plans Canadian regulatory clearance and market entry – 10 June 2020 

PainChek® granted Australian patent for pain assessment invention – 8th May 2020

PainChek® achieves 50% + growth in aged care beds, clients and facilities during March 2020 quarter – 30 April 2020

Appendix 4C – Quarterly cash flow report for entities subject to Listing Rule 4.7B – 31 March 2020

PainChek® submits FDA Pre-Submission Supplement- 14 April 2020